Abstract
Obesity and associated comorbidities, including non-alcoholic fatty liver disease (NAFLD), are a major concern to public well-being worldwide due to their high prevalence among the population, and its tendency on the rise point to as important threats in the future. Therapeutic approaches for obesity-associated disorders have been circumscribed to lifestyle modifications and pharmacological therapies have demonstrated limited efficacy. Over the last few years, different studies have shown a significant role of intestinal microbiota (IM) on obesity establishment and NAFLD development. Therefore, modulation of IM emerges as a promising therapeutic strategy for obesity-associated diseases. Administration of prebiotic and probiotic compounds, fecal microbiota transplantation (FMT) and exercise protocols have shown a modulatory action over the IM. In this review we provide an overview of current approaches targeting IM which have shown their capacity to counteract NAFLD and metabolic syndrome features in human patients and animal models.
Highlights
Reviewed by: Manlio Vinciguerra, International Clinical Research Center (FNUSA-ICRC), Czechia Juan Antonio Rosado Dionisio, Universidad de Extremadura, Spain
In this review we provide an overview of current approaches targeting intestinal microbiota (IM) which have shown their capacity to counteract non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome features in human patients and animal models
Intestinal microbiota dysbiosis and related gut-liver axis activation are accepted as a critical process in NAFLD development
Summary
Reviewed by: Manlio Vinciguerra, International Clinical Research Center (FNUSA-ICRC), Czechia Juan Antonio Rosado Dionisio, Universidad de Extremadura, Spain. Obesity and associated comorbidities, including non-alcoholic fatty liver disease (NAFLD), are a major concern to public well-being worldwide due to their high prevalence among the population, and its tendency on the rise point to as important threats in the future. In the case of obesity, the link with NAFLD is especially important since 75–92% of morbidity obese individuals present some degree of fatty liver (Fazel et al, 2016). This association implies that NAFLD will be more common in the near future due to the global epidemic of obesity, with more than 1,900 million people being overweight and more than 600 million obese in 2014 (World Health Organization, 2016). The disease can progress into more severe conditions such as non-alcoholic steatohepatitis, fibrosis, cirrhosis or even hepatocellular carcinoma (Tiniakos et al, 2010)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
